Track topics on Twitter Track topics that are important to you
Dr Francois-Clement Bidard gives a press conference at SABCS 2018 about the results from the phase III STIC CTC trial, where circulating tumour-cell count was used to decide between hormone therapy or...
Dr Francois-Clement Bidard speaks to ecancer at SABCS 2018 about the results from the phase III STIC CTC trial, where circulating tumour-cell count was used to decide between hormone therapy or chemot...
(American Association for Cancer Research) Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positiv...
Vasa previa is a rare condition; it occurs in approximately 1:2500 deliveries. Fetal blood vessels, unsupported by placental tissues or umbilical cord, run through the fetal membrane over the internal...
Histocompatibility testing, and HLA antibody screening in particular, varies in practice among laboratories. Currently, standards are lacking regarding the reporting of testing methods in publications...
Ovarian cancer remains the leading cause of gynecologic cancer death among American women. Prevention is the only proven approach to reduce the incidence of the disease. Oral contraception, tubal liga...
The objective of this study is to use of STIC technology to assist the traditional echocardiography to dignose the fetal congenital heart disease accurately and then to provide a basis for...
L’Hospital Universitari Sagrat Cor és l’hospital de titularitat privada més gran de Barcelona, amb una capacitat de 350 llits i tecnologia mèdica i serveis hotelers de primer nivell. L’Hospit...
We have published hundreds of STIC.NET news stories on BioPortfolio along with dozens of STIC.NET Clinical Trials and PubMed Articles about STIC.NET for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of STIC.NET Companies in our database. You can also find out about relevant STIC.NET Drugs and Medications on this site too.